Open Access

Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia

  • Chau-To Kwok1, 2, 3,
  • Amy D. Marshall1, 3,
  • John E. J. Rasko1, 3, 4 and
  • Justin J. L. Wong1, 2, 3Email author
Journal of Hematology & Oncology201710:49

https://doi.org/10.1186/s13045-017-0419-x

Received: 8 February 2017

Accepted: 8 February 2017

Published: 17 February 2017

The original article was published in Journal of Hematology & Oncology 2017 10:39

Erratum

The original article [1] contained an error whereby the formatting of Table 1 was not presented correctly; this error has now been corrected.
Table 1

Clinical and molecular characteristics of TCGA AML patients according to the mutation and/or copy number variation status of genes encoding m6A regulatory enzymes

 

Mutation and/or CNV

CNV onlya

Mutation

 

Yes (n = 23)

No (n = 168)

P

Yes (n = 18)

No (n = 168)

P

Yes (n = 5)

No (n = 186)

P

Age

  

0.083

  

0.193

  

0.205

Median (range)

65 (18–81)

57 (21–88)

 

62.5 (18–81)

57 (21–88)

 

65 (45–76)

57.5 (18–88)

 

Sex, no. (%)

  

0.123

  

0.321

  

0.376

Male

16 (8.4)

87 (45.5)

 

12 (6.5)

87 (46.8)

 

4 (2.1)

99 (51.8)

 

Female

7 (3.7)

81 (42.4)

 

6 (3.2)

81 (43.5)

 

1 (0.5)

87 (45.5)

 

BM blast

  

0.072

  

0.038

  

0.915

Median % (range)

60 (30–97)

73 (30–100)

 

54 (30–97)

73 (30–100)

 

75 (33–90)

72 (30–100)

 

WBC, ×103/mm3

  

0.084

  

0.047

  

0.889

Median (range)

5.4 (0.7–202.7)

17.5 (0.4–298.4)

 

5.2 (2.3–101.3)

17.45 (0.4–298.4)

 

14.5 (2.3–101.3)

15.6 (0.4–298.4)

 

Cytogenetic risk, no. (%)

  

<0.0001

  

<0.0001

  

0.483

Favorable

0 (0)

37 (19.4)

 

0 (0)

37 (19.9)

 

0 (0)

37 (19.4)

 

Intermediate

4 (2.1)

105 (55)

 

1 (0.5)

105 (56.5)

 

3 (1.6)

106 (55.5)

 

Unfavorable

19 (9.9)

21 (11)

 

17 (9.1)

21 (11.3)

 

2 (1)

38 (19.9)

 

Missing data

0 (0)

5 (2.6)

 

0 (0)

5 (2.6)

 

0 (0)

5 (2.6)

 

Mutation, no./total no. (%)

 FLT3

1/23 (4.3)

53/168 (31.5)

0.005

0/18 (0)

53/168 (31.5)

0.002

1/5 (20)

53/186 (28.4)

1.000

 NPM1

1/23 (4.3)

51/168 (30)

0.006

0/18 (0)

51/168 (30.3)

0.004

1/5 (20)

51/186 (27.4)

1.000

 DNMT3A

4/23 (17.4)

43/168 (25.6)

0.453

2/18 (11.1)

43/168 (25.6)

0.249

2/5 (40)

45/186 (24.2)

0.598

 IDH1 or IDH2

1/23 (4.3)

34/168 (20.2)

0.084

0/18 (0)

34/168 (20.2)

0.048

1/5 (20)

34/186 (18.3)

1.000

 NRAS or KRAS

3/23 (13)

20/168 (11.9)

0.744

3/18 (16.7)

20/168 (11.9)

0.471

0/5 (0)

23/186 (12.4)

1.000

 RUNX1

2/23 (8.7)

17/168 (10.1)

1.000

0/18 (0)

17/168 (10.1)

0.380

2/5 (40)

17/186 (9.1)

0.078

 TET2

1/23 (4.3)

15/168 (8.9)

0.698

1/18(5.6)

15/168 (8.9)

1.000

0/5 (0)

16/186 (8.6)

1.000

 TP53

15/23 (65.2)

1/168 (0.6)

<0.0001

13/18 (72.2)

1/168 (0.6)

<0.0001

2/5 (40)

14/186 (7.5)

0.057

 CEBPA

2/23 (8.7)

10/168 (6.0)

0.641

2/18 (11.1)

10/168 (6.0)

0.327

0/5 (0)

12/186 (6.5)

1.000

 WT1

0/23 (0)

12/168 (7.1)

0.366

0/18 (0)

12/168 (7.1)

0.610

0/5 (0)

12/186 (6.5)

1.000

 PTPN11

2/23 (8.7)

6/168 (3.6)

0.248

2/18 (11.1)

6/168 (3.6)

0.175

0/5 (0)

8/186 (4.3)

1.000

 KIT

1/23 (4.3)

6/168 (3.6)

0.599

0/18 (20)

6/168 (3.6)

1.000

1/5 (20)

6/186 (3.2)

0.172

Significant P values are in bold

CNV copy number variation, BM bone marrow, WBC white blood cell

aExcluding samples with m6A regulatory gene mutations

Furthermore, the error was mistakenly carried forward by the production team handling this article, and thus was not the fault of the authors.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Gene & Stem Cell Therapy Program, Centenary Institute, University of Sydney
(2)
Gene Regulation in Cancer Laboratory, Centenary Institute, University of Sydney
(3)
Sydney Medical School, University of Sydney
(4)
Cell and Molecular Therapies, Royal Prince Alfred Hospital

References

  1. Kwok, et al. Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia. J Hematol Oncol. 2017;10:39.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement